Erectile Dysfunction Market
Number of pages: 100 | Report Format: PDF | Published date: 29 November, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 2.10 billion |
|
Revenue forecast in 2030 |
US$ 4.30 billion |
|
Growth Rate |
CAGR of 8.3% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
drug, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global erectile dysfunction market was pegged at US$ 2.10 billion in 2021 and is expected to register a revenue CAGR of 8.3% during the forecast period.
Market Fundamentals
Erectile dysfunction is defined as the inability to achieve or maintain a robust sufficient penile erection during sexual intercourse. It is the most common male sexual health issue. Erectile dysfunction has two primary causes: psychological and physiological. High blood pressure, high cholesterol, obesity, diabetes, smoking, and tobacco consumption are all physiological causes. While stress is a key psychological factor causing erectile dysfunction.
[3424343]
Market Dynamic
A sedentary lifestyle, associated stress, the rising geriatric population, and the comorbidity between erectile dysfunction, diabetes, and cardiovascular diseases are some of the factors driving the erectile dysfunction (ED) drug market. A sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increased acceptance of such negative lifestyle choices is expected to propel the market revenue growth during the forecast period.
Market Ecosystem
The global erectile dysfunction market has been analyzed from three perspectives, drug, distribution channel, and region.
Erectile Dysfunction Market by Drugs
[423423]
Based on drug type, the global erectile dysfunction market has been subdivided into, Sildenafil, Tadalafil, Vardenafil, Alprostadil, Avanafil, and Udenafil. The drug segment Sildenafil is the first line of treatment for erectile dysfunction. Sildenafil is a powerful and discriminatory PDE-5 inhibitor and the first medication acknowledged for erectile dysfunction treatment. The market for sildenafil will be driven by the aging population as well as the rising prevalence of chronic conditions like hypertension and hormonal deficiencies.
Erectile Dysfunction Market by Distribution Channel
Based on end-user, the global erectile dysfunction market has been divided into, hospital pharmacy, retail pharmacy, and online pharmacy. The presence of drugs for the treatment of erectile dysfunction over the counter is responsible for the dominance of the retail pharmacy segment.
Erectile Dysfunction Market by Region
Based on region, the global erectile dysfunction market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to its growing elderly population, rise in erectile dysfunction cases, and superior healthcare infrastructure, North America is expected to dominate the market for erectile dysfunction medications.
When the final cohort of baby boomers reaches the age of 65 in 2030, the number of older persons is projected to increase by around 18 million. Given that ED is particularly common in males over the age of 40, the number of patients with the condition is anticipated to climb as the elderly male population grows.
Competitive Landscape
Some of the prominent players operating in the global erectile dysfunction market are: -
Strategic Developments
• In May 2022, Aspargo Laboratories, Inc. acquired the prescription brand Bandol from the Spanish specialty pharmaceutical company Laboratorios Rubio S.A.
The global erectile dysfunction market is expected to register a revenue CAGR of 8.3% during the forecast period.
Pfizer Inc., Eli Lilly & Company, among others. are the key players in the global erectile dysfunction market.
The Sildenafil drug segment dominates the global erectile dysfunction market.
Asia Pacific region is expected to register the highest revenue growth in the global erectile dysfunction market during the forecast period.
*Insights on financial permanence are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst